Exatecan Mesylate
| Title | Journal |
|---|---|
| Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. | Expert review of anticancer therapy 20080501 |
| Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. | Biological & pharmaceutical bulletin 20071201 |
| Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? | Pediatric blood & cancer 20070801 |
| Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. | European journal of cancer (Oxford, England : 1990) 20070401 |
| Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f. | Journal of pharmaceutical and biomedical analysis 20070312 |
| Exatecan and gemcitabine: no better than gemcitabine only. | The Lancet. Oncology 20061101 |
| Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060920 |
| Chemotherapy for advanced pancreatic cancer. | Best practice & research. Clinical gastroenterology 20060401 |
| A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. | Investigational new drugs 20051001 |
| DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. | Investigational new drugs 20050801 |
| A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. | American journal of clinical oncology 20050801 |
| Chemotherapeutic gemcitabine doublets in pancreatic carcinoma. | Seminars in oncology 20050801 |
| Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050425 |
| A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. | Cancer chemotherapy and pharmacology 20050401 |
| Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. | Biomedical chromatography : BMC 20050101 |
| Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. | Thrombosis and haemostasis 20041201 |
| A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. | Gynecologic oncology 20041001 |
| A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041001 |
| Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice. | Die Pharmazie 20040501 |
| DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models. | Cancer science 20040201 |
| A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. | Cancer chemotherapy and pharmacology 20040101 |
| A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. | Investigational new drugs 20040101 |
| Are there any better camptothecins than the ones we have? | Clinical advances in hematology & oncology : H&O 20031001 |
| A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. | Cancer 20030901 |
| Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030701 |
| Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies. | Annals of oncology : official journal of the European Society for Medical Oncology 20030601 |
| [A symphony for the camptothecins]. | Bulletin du cancer 20030301 |
| Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. | Cancer research 20030101 |
| The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. | Biochemical pharmacology 20021015 |
| Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. | British journal of cancer 20020909 |
| Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020701 |
| [Drug delivery systems for cancer chemotherapy]. | Nihon Geka Gakkai zasshi 20020201 |
| O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. | Japanese journal of cancer research : Gann 20020101 |
| Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. | Biomedical chromatography : BMC 20010401 |
| Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301 |
| High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma. | Biological & pharmaceutical bulletin 20010201 |
| Morphological classification of dental lesions induced by various antitumor drugs in mice. | Toxicologic pathology 20010101 |